Fungi · Scientific monograph
Trametes versicolor
Turkey Tail
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Immunological Research, Cellular & Immune Studies, Gut Microbiota Research
Research overview
Historical use
Used in Traditional Chinese Medicine as 'Yun Zhi' (cloud mushroom) for over 2,000 years for liver ailments, infections, and as a general tonic. In Japan, the polysaccharide extract PSK (Krestin) was developed in the 1970s and became one of the best-selling anti-cancer drugs in the world, approved for clinical use in Japan.
Modern research context
PSK (polysaccharide-K) and PSP (polysaccharide-peptide) are the most clinically studied compounds [2]. A Phase 1 clinical trial in women with breast cancer demonstrated safety and immune enhancement following oral administration [1]. PSP shows anti-proliferative activity against colorectal cancer cells via multiple molecular targets [3]. Immunomodulatory potential in the context of cancer and infectious disease is under continued investigation [4]. Clinical data supports its role as an adjunct in oncology when used alongside conventional chemotherapy [2][5].
Adverse effects
Generally very well tolerated. Mild GI symptoms (nausea, diarrhoea) at high doses. Rare hypersensitivity. Darkening of fingernails reported with PSK in some trials. Mild hepatotoxicity at very high doses in animal studies.
Contraindications
Caution with immunosuppressants (pharmacodynamic antagonism). Avoid in known mushroom allergy. Caution pre-surgery.
Clinical and phytochemical data
Used part
Fruiting body
Primary active compounds
PSK / Krestin (polysaccharide-K, protein-bound)
PSP (polysaccharide-peptide)
Beta-1,3/1,4-glucans
Ergosterol
Phenolic compounds (quercetin, kaempferol)
Mechanism of action
PSK and PSP bind to TLR-2 and Dectin-1 on macrophages and dendritic cells, activating innate immunity. Stimulates NK cell cytotoxicity and T-helper cell polarisation. PSK upregulates IL-2, IFN-γ production. Antioxidant via direct radical scavenging. Prebiotic effect on Bifidobacterium and Lactobacillus populations in the gut.
Pharmacokinetics
Absorption
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — PSK is a high-molecular-weight glycoprotein with limited systemic oral absorption; primarily acts at gut-associated lymphoid tissue (GALT) and is partially absorbed in lower molecular weight fractions.
Distribution
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — PSK distributes primarily to GALT, spleen, and peripheral lymphoid organs after partial oral absorption. Animal studies demonstrate accumulation in lymphoid tissue and tumour microenvironment. High molecular weight limits CNS penetration. No human plasma protein binding or quantitative tissue distribution data are available.
Metabolism
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Partially hydrolysed in the GI tract; absorbed fractions undergo hepatic metabolism.
Excretion
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Primarily fecal; some renal excretion of smaller absorbed fragments.
Safety and interactions
Drug interactions
Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.
Toxicity
PSK LD50 >20 g/kg (oral, mice). In Japanese post-marketing surveillance of millions of doses, serious adverse events are extremely rare. Mild, reversible liver enzyme elevations at doses >6 g/day in some individuals.
Special precautions
Pregnancy
Insufficient human clinical data. Avoid during pregnancy due to lack of controlled safety studies.
Lactation
No data on excretion in breast milk. Avoid during breastfeeding.
Hepatic impairment
Mild ALT/AST elevations noted at high doses; use cautiously with hepatic impairment and monitor liver function.
Renal impairment
No specific dose adjustment data available. Use with standard monitoring.
Sources and references
- [1] - Torkelson CJ., "Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer.", ISRN Oncol, 2012, PMID: 22701186
- [2] - Habtemariam S., "Trametes versicolor (Synn. Coriolus versicolor) Polysaccharides in Cancer Therapy: Targets and Efficacy.", Biomedicines, 2020, PMID: 32466253
- [3] - He Z., "Polysaccharide-Peptide from Trametes versicolor: The Potential Medicine for Colorectal Cancer Treatment.", Biomedicines, 2022, PMID: 36359361
- [4] - Jędrzejewski T., "COVID-19 and Cancer Diseases-The Potential of Coriolus versicolor Mushroom to Combat Global Health Challenges.", Int J Mol Sci, 2023, PMID: 36902290
- [5] - Łysakowska P., "Medicinal Mushrooms: Their Bioactive Components, Nutritional Value and Application in Functional Food Production-A Review.", Molecules, 2023, PMID: 37513265